Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Targeting IL-33 to treat Crohn's disease-associated fibrosis

EF 2022-23

Résumé
Crohn's Disease (CD) is an inflammatory bowel disease. It involves inflammation that discontinuously occurs anywhere from the lips to the anus and penetrates all layers of the intestine. 1 in 3 people with CD will develop a life threatening complication called fibrosis. Fibrosis is an uncontrolled healing response which results in deposition of excessive extracellular matrix components (ECM) such as collagen and thickening of the muscle layer. The bowel will become blocked. There are no current drugs to treat fibrosis, surgery is the only intervention. However, it is not effective as fibrosis is a self-perpetuating process that will continue to propagate despite surgery. Thus, it is imperative to understand the mechanisms involved with fibrosis in order to identify a target for the world's first therapeutic to treat intestinal fibrosis. My project will investigate IL-33 as a target to treat intestinal fibrosis. IL-33 is a compelling target to investigate within the context of CD-associated fibrosis as previous studies have established its pro-fibrotic role in lung fibrosis. Moreover, IL-33 concentrations are increased in biopsies of people with CD. I hypothesize fibrosis in CD is dependent on IL-33. In order to test this, I will be using a CD-associated fibrosis mouse model developed by the Sly lab. I will be targeting IL-33 with neutralizing antibodies in both the CD mouse model and wildtype (WT) control mice. Male and female mice will be included in equal numbers. I will also be doing genetic deletion of IL33 in the CD model and WT mice. To asses changes in fibrotic pathology, I will be employing techniques such as immunofluorescence, RT-qPCR, collagen assay and histological scoring. This research could potentially find a target for treating intestinal fibrosis.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486171
Name
Sekhon Prabhreet
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting IL-33 to treat Crohn's disease-associated fibrosis
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antibody; Crohn'S; Ecm; Fibrosis; Genetic Ablation; Ibd; Il-33; Mouse; Pro-Fibrotic; Therapeutic
Abstract
Crohn's Disease (CD) is an inflammatory bowel disease. It involves inflammation that discontinuously occurs anywhere from the lips to the anus and penetrates all layers of the intestine. 1 in 3 people with CD will develop a life threatening complication called fibrosis. Fibrosis is an uncontrolled healing response which results in deposition of excessive extracellular matrix components (ECM) such as collagen and thickening of the muscle layer. The bowel will become blocked. There are no current drugs to treat fibrosis, surgery is the only intervention. However, it is not effective as fibrosis is a self-perpetuating process that will continue to propagate despite surgery. Thus, it is imperative to understand the mechanisms involved with fibrosis in order to identify a target for the world's first therapeutic to treat intestinal fibrosis. My project will investigate IL-33 as a target to treat intestinal fibrosis. IL-33 is a compelling target to investigate within the context of CD-associated fibrosis as previous studies have established its pro-fibrotic role in lung fibrosis. Moreover, IL-33 concentrations are increased in biopsies of people with CD. I hypothesize fibrosis in CD is dependent on IL-33. In order to test this, I will be using a CD-associated fibrosis mouse model developed by the Sly lab. I will be targeting IL-33 with neutralizing antibodies in both the CD mouse model and wildtype (WT) control mice. Male and female mice will be included in equal numbers. I will also be doing genetic deletion of IL33 in the CD model and WT mice. To asses changes in fibrotic pathology, I will be employing techniques such as immunofluorescence, RT-qPCR, collagen assay and histological scoring. This research could potentially find a target for treating intestinal fibrosis.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sekhon, Prabhreet
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~